Heterogeneity in Melanoma.

[1]  Maria L. Wei,et al.  Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma , 2015, Melanoma research.

[2]  Ryan E O'Leary,et al.  Update on tanning: More risks, fewer benefits. , 2014, Journal of the American Academy of Dermatology.

[3]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[4]  B. Bastian.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. , 2014, Annual review of pathology.

[5]  A. Weeraratna,et al.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.

[6]  A. Tward,et al.  High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma , 2013, Cancer.

[7]  R. Tothill,et al.  BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage , 2013, Clinical Cancer Research.

[8]  J. Wilmott,et al.  Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression , 2013, Pigment cell & melanoma research.

[9]  P. Gimotty,et al.  Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.

[10]  A. Bovier,et al.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? , 2013, Nature Reviews Cancer.

[11]  M. Vitale.  Intratumor BRAFV600E heterogeneity and kinase inhibitors in the treatment of thyroid cancer: a call for participation. , 2013, Thyroid : official journal of the American Thyroid Association.

[12]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[13]  H. Pehamberger,et al.  The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells , 2013, Clinical Cancer Research.

[14]  A. Casadevall,et al.  Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy. , 2013, Nuclear medicine and biology.

[15]  H. Clevers,et al.  Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties , 2013, Cell.

[16]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[17]  M. McCarter,et al.  ALDH1A Isozymes are Markers of Human Melanoma Stem Cells and Potential Therapeutic Targets , 2012, Stem cells.

[18]  J. Wilmott,et al.  Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine , 2012, Molecular Cancer Therapeutics.

[19]  P. Kulesa,et al.  Melanoma revives an embryonic migration program to promote plasticity and invasion , 2012, Pigment cell & melanoma research.

[20]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[21]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[22]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[23]  M. Czyz,et al.  Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment , 2012, Melanoma research.

[24]  S. Middendorp,et al.  Plasticity of melanoma cells induced by neural cell crest conditions and three-dimensional growth , 2012, Melanoma research.

[25]  P. Bahadoran,et al.  Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells , 2012, Oncogene.

[26]  D. Hunter,et al.  Use of tanning beds and incidence of skin cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Wagner,et al.  Targeting CD20 in melanoma patients at high risk of disease recurrence. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  M. Adams,et al.  Characterizing Mutational Heterogeneity in a Glioblastoma Patient with Double Recurrence , 2012, PloS one.

[29]  S. Middendorp,et al.  Nanog and Oct4 overexpression increases motility and transmigration of melanoma cells , 2012, Journal of Cancer Research and Clinical Oncology.

[30]  M. Mazumdar,et al.  Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma , 2012, PloS one.

[31]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[32]  D. Radisky,et al.  TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. , 2011, Cancer research.

[33]  M. Herlyn,et al.  Dermis‐derived stem cells: a source of epidermal melanocytes and melanoma? , 2011, Pigment cell & melanoma research.

[34]  H. Moch,et al.  Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. , 2011, Cancer research.

[35]  H. Schaider,et al.  The cadherin switch in melanoma instigated by HGF is mediated through epithelial–mesenchymal transition regulators , 2011, Pigment cell & melanoma research.

[36]  H. Abken,et al.  Eradication of melanomas by targeted elimination of a minor subset of tumor cells , 2011, Proceedings of the National Academy of Sciences.

[37]  K. Anderson,et al.  Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.

[38]  T. Saida,et al.  Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression , 2011, British Journal of Cancer.

[39]  Brian J. Wilson,et al.  VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. , 2011, Cancer research.

[40]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[41]  P. Pollock,et al.  p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation , 2010, Pigment cell & melanoma research.

[42]  Ying Lu,et al.  Selection of tumorigenic melanoma cells using ALDH. , 2010, The Journal of investigative dermatology.

[43]  S. Morrison,et al.  Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. , 2010, Cancer cell.

[44]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[45]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[46]  G. Mælandsmo,et al.  Aldehyde Dehydrogenase (ALDH) Activity Does Not Select for Cells with Enhanced Aggressive Properties in Malignant Melanoma , 2010, PloS one.

[47]  Irving L. Weissman,et al.  Human Melanoma Initiating Cells Express Neural Crest Nerve Growth Factor Receptor CD271 , 2010, Nature.

[48]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[49]  A. Kossenkov,et al.  Stem cells with neural crest characteristics derived from the bulge region of cultured human hair follicles. , 2010, The Journal of investigative dermatology.

[50]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[51]  M. Herlyn,et al.  Human dermal stem cells differentiate into functional epidermal melanocytes , 2010, Journal of Cell Science.

[52]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[53]  F. Hodi,et al.  Tumor and Stem Cell Biology Cancer Research Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells , 2010 .

[54]  P. Pollock,et al.  Active Notch1 confers a transformed phenotype to primary human melanocytes. , 2009, Cancer research.

[55]  G. Maira,et al.  Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution , 2009, Oncogene.

[56]  S. Morrison,et al.  Efficient tumor formation by single human melanoma cells , 2008, Nature.

[57]  Mohamed H. Sayegh,et al.  Identification of cells initiating human melanomas , 2008, Nature.

[58]  Caterina A M La Porta,et al.  Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. , 2007, European journal of cancer.

[59]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[60]  Hailing Lu,et al.  Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition1 , 2006, The Journal of Immunology.

[61]  F. Lozupone,et al.  Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma , 2006, Oncogene.

[62]  Carissa A. Sanchez,et al.  Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.

[63]  D. Elder,et al.  A tumorigenic subpopulation with stem cell properties in melanomas. , 2005, Cancer research.

[64]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[65]  F. Haluska,et al.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.

[66]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[67]  D. Hunt,et al.  Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens , 2000, Cancer Immunology, Immunotherapy.

[68]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[69]  D. Bowtell,et al.  A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. , 2012, Cancer research.

[70]  Shuping Zhao,et al.  Increased expression of stem cell markers in malignant melanoma , 2007, Modern Pathology.